RecruitingNCT06127290
HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
Sponsor
Euresist Network GEIE
Enrollment
200 participants
Start Date
Dec 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- naïve patients starting 2nd generation INSTI treatment
- first line patients under 2nd generation INSTI treatment with either viral RNA sequence before therapy start, or PBMC available with PBMC sample date not more than 3 years from therapy start date (with reasonably sure history of no failure in the interval from therapy start date to PBMC sample date\]).
Exclusion Criteria2
- patients not having a signed informed consent for the EIDB data repository, if required by local/national legislation in order to have data in the common data repository.
- patients not having Signed Informed consent for the present study, if required by local authorities iii) Persons aged \< 18 at baseline
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06127290
Related Trials
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
NCT073923723 locations
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
NCT0633703214 locations
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
NCT070554517 locations
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
NCT0729355911 locations
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
NCT0721546811 locations